Agilent Technologies, Inc. $A Shares Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. reduced its position in shares of Agilent Technologies, Inc. (NYSE:A) by 16.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 586,625 shares of the medical research company’s stock after selling 112,680 shares during the quarter. Russell Investments Group Ltd. owned 0.21% of Agilent Technologies worth $75,190,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of A. Envestnet Asset Management Inc. lifted its stake in Agilent Technologies by 3.8% in the 3rd quarter. Envestnet Asset Management Inc. now owns 607,914 shares of the medical research company’s stock valued at $78,026,000 after buying an additional 22,498 shares in the last quarter. CCLA Investment Management increased its stake in Agilent Technologies by 10.5% during the 3rd quarter. CCLA Investment Management now owns 1,027,970 shares of the medical research company’s stock worth $131,909,000 after buying an additional 97,312 shares in the last quarter. Osaic Holdings Inc. increased its stake in Agilent Technologies by 35.5% during the 2nd quarter. Osaic Holdings Inc. now owns 68,053 shares of the medical research company’s stock worth $8,017,000 after buying an additional 17,817 shares in the last quarter. Fenimore Asset Management Inc raised its holdings in shares of Agilent Technologies by 224.2% during the third quarter. Fenimore Asset Management Inc now owns 586,500 shares of the medical research company’s stock valued at $75,277,000 after acquiring an additional 405,620 shares during the last quarter. Finally, First Horizon Corp purchased a new position in shares of Agilent Technologies in the third quarter valued at approximately $1,378,000.

Key Headlines Impacting Agilent Technologies

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Acquisition: Agilent agreed to buy Biocare Medical for $950M in an all‑cash deal to strengthen its pathology and diagnostics portfolio, adding high‑growth IHC/FISH capabilities that complement Agilent’s life‑sciences and diagnostics end markets. Agilent to Acquire Biocare Medical, a Global Leader in Clinical and Research Pathology Solutions
• Positive Sentiment: Immediate market reaction: Several outlets reported the stock rallied on the acquisition announcement, reflecting investor recognition of the strategic fit and near‑term revenue diversification benefits. Agilent stock rises on $950M Biocare Medical acquisition
• Neutral Sentiment: Analyst stance: Despite recent underperformance vs. the S&P 500, analysts cited by coverage remain optimistic about Agilent’s longer‑term growth prospects and the strategic rationale for the acquisition. Is Agilent Technologies Stock Underperforming the S&P 500?
• Neutral Sentiment: Deal details and rationale: Reuters/press coverage notes the transaction is all‑cash and framed as a bolt‑on to accelerate Agilent’s presence in clinical pathology markets — the operational and margin implications will depend on integration and cross‑sell execution. Agilent to acquire Biocare Medical in $950 million all-cash deal
• Negative Sentiment: Muted investor response: Some reports show the buyout didn’t fully offset investor concerns after Agilent’s slight Q1 earnings/revenue miss and ongoing valuation/relative‑performance pressure, causing the stock to slip in some sessions. Agilent stock slips premarket: $950M Biocare buyout fails to lift investor sentiment after Q1 miss

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on A. The Goldman Sachs Group initiated coverage on Agilent Technologies in a research note on Tuesday, December 9th. They issued a “buy” rating and a $170.00 price target on the stock. Citigroup raised their price objective on Agilent Technologies from $165.00 to $185.00 and gave the company a “buy” rating in a report on Tuesday, November 25th. Wells Fargo & Company lowered their target price on shares of Agilent Technologies from $175.00 to $165.00 and set an “overweight” rating on the stock in a research note on Thursday, February 26th. JPMorgan Chase & Co. upped their target price on shares of Agilent Technologies from $165.00 to $180.00 and gave the stock an “overweight” rating in a report on Tuesday, November 25th. Finally, Morgan Stanley reduced their target price on shares of Agilent Technologies from $180.00 to $160.00 and set an “overweight” rating for the company in a research report on Tuesday, March 3rd. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $161.20.

Agilent Technologies Stock Down 1.0%

Shares of NYSE:A opened at $115.46 on Wednesday. The company has a quick ratio of 1.59, a current ratio of 2.07 and a debt-to-equity ratio of 0.44. The business has a fifty day moving average of $131.78 and a two-hundred day moving average of $136.07. The stock has a market cap of $32.63 billion, a P/E ratio of 25.49, a PEG ratio of 2.46 and a beta of 1.31. Agilent Technologies, Inc. has a 52-week low of $96.43 and a 52-week high of $160.27.

Agilent Technologies (NYSE:A) last posted its quarterly earnings results on Wednesday, February 25th. The medical research company reported $1.36 EPS for the quarter, missing the consensus estimate of $1.37 by ($0.01). The company had revenue of $1.80 billion for the quarter, compared to analysts’ expectations of $1.81 billion. Agilent Technologies had a return on equity of 24.49% and a net margin of 18.26%.The firm’s revenue was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.31 EPS. Agilent Technologies has set its FY 2026 guidance at 5.900-6.040 EPS and its Q2 2026 guidance at 1.390-1.420 EPS. On average, research analysts expect that Agilent Technologies, Inc. will post 5.58 earnings per share for the current year.

Agilent Technologies Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 22nd. Shareholders of record on Tuesday, March 31st will be issued a $0.255 dividend. This represents a $1.02 annualized dividend and a yield of 0.9%. The ex-dividend date is Tuesday, March 31st. Agilent Technologies’s payout ratio is presently 22.52%.

Agilent Technologies Profile

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.